Synthesis and grafting of folate–PEG–PAMAM conjugates onto quantum dots for selective targeting of folate-receptor-positive tumor cells

Zhao, Yili; Liu, Sen; Li, Yapeng; Jiang, Wei; Chang, Yulei; Pan, Si; Fang, Xuexun; Wang, Y. Andrew; Wang, Jingyuan

doi:10.1016/j.jcis.2010.05.035

Cited by 66 publications

(40 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Another example of the development of FA-PEG-G3.5 PAMAM conjugates onto quantum dots (QDs) in HeLa tumor cells has been described by Zhao et al [25]. Significant cellular uptake was observed based on in vivo imaging experiments.…”

Section: Dendrimers For Theranostic Applicationsmentioning

confidence: 99%

See 1 more Smart Citation

Recent therapeutic applications of the theranostic principle with dendrimers in oncology

et al. 2018

View full text Add to dashboard Cite

Section: Dendrimers For Theranostic Applicationsmentioning

confidence: 99%

“…Thus, Zhao and coworkers [25] developed folate-PEG-3.5-PAMAM dendrimers encapsulating luminescent CdSe/ZnS QDs as an imaging agent for selective targeting of FR-positive tumor cells. In this construction, 3.5 PAMAM dendrimers were used to encapsulate QDs.…”

Section: Optical Imagingmentioning

confidence: 99%

Recent therapeutic applications of the theranostic principle with dendrimers in oncology

et al. 2018

View full text Add to dashboard Cite

“…23,24 Moreover, FA is a relatively small molecule (MW 441 Da) that consequently has only limited effects on the dimensions of the carrier system, high stability, compatibility with both organic and aqueous solvent, low cost, non-immunogenic character and the ability to conjugate with a wide variety of molecules, so it has attracted wide attention as a targeting agent. 25 So far, some papers regarding folate-appended dendrimers have been published. For example, Konda et al 26 reported the novel folate dendrimer magnetic resonance imaging contrast agents to the high affinity FR expressed in ovarian tumor xenografts.…”

Section: Introductionmentioning

confidence: 99%

Potential use of folate-polyethylene glycol (PEG)-appended dendrimer (G3) conjugate with α-cyclodextrin as DNA carriers to tumor cells

et al. 2012

View full text Add to dashboard Cite

We previously reported that polyamidoamine STARBURST dendrimer (generation 3, G3) (dendrimer) conjugate with a-cyclodextrin (a-CyD) having an average degree of substitution of 2.4 of a-CyD (a-CDE) provided remarkable aspects as novel carriers for DNA and small-interfering RNA. To develop novel a-CDE derivatives with tumor cell specificity, we prepared folate-appended a-CDEs (Fol-a-CDEs) and folate-polyethylene glycol (PEG)-appended a-CDEs (Fol-PaCs) with the various degrees of substitution of folate (DSF), and evaluated in vitro and in vivo gene transfer activity, cytotoxicity, cellular association and physicochemical properties. In vitro gene transfer activity of Fol-a-CDEs (G3, DSF 2, 5 or 7) was lower than that of a-CDE (G3) in KB cells, folate receptor (FR)-overexpressing cancer cells. Of the three Fol-PaCs (G3, DSF 2, 5 or 7), Fol-PaC (G3, DSF 5) had the highest gene transfer activity in KB cells. The activity of Fol-PaC (G3, DSF 5) was significantly higher than that of a-CDE (G3) in KB cells, but not in A549 cells, FR-negative cells. Negligible cytotoxicity of the plasmid DNA (pDNA) complex with Fol-PaC (G3, DSF 5) was observed in KB cells or A549 cells up to a charge ratio of 100/1 (carrier/pDNA). The cellular association of the pDNA complex with Fol-PaC (G3, DSF 5) could be mediated by FR on KB cells, resulting in its efficient cellular uptake. Fol-PaC (G3, DSF 5) had a higher binding affinity with folate-binding protein than a-CDE (G3), although the physicochemical properties of pDNA complex with Fol-PaC (G3, DSF 5) were almost comparable to that with a-CDE (G3), although the onset charge ratio and the compaction ability of Fol-PaC (G3, DSF 5) were slightly different. Fol-PaC (G3, DSF 5) tended to show a higher gene transfer activity than a-CDE (G3) 12 h after intratumoral administration in mice. These results suggest that Fol-PaC (G3, DSF 5), not Fol-a-CDEs, could be potentially used as a FR-overexpressing cancer cell-selective DNA carrier.

show abstract

“…5 However, it cannot achieve sufficiently high levels of drug concentration in tumor tissues by passive targeting, 6,7 with only a small amount of drug being taken by tumor cells. To improve targeting efficiency and reduce side effects, introducing targeting molecules, such as folic acid [8][9][10] or peptides, [11][12][13] into polymeric micelles is necessary because they can recognize and bind to specific receptors unique to tumor cells.…”

Section: Introductionmentioning

confidence: 99%

Octreotide-Modified N-Octyl-O, N-Carboxymethyl Chitosan Micelles as Potential Carriers for Targeted Antitumor Drug Delivery

Zou

Huo

Zhang

et al. 2012

Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

Synthesis and grafting of folate–PEG–PAMAM conjugates onto quantum dots for selective targeting of folate-receptor-positive tumor cells

Cited by 66 publications

References 44 publications

Recent therapeutic applications of the theranostic principle with dendrimers in oncology

Recent therapeutic applications of the theranostic principle with dendrimers in oncology

Potential use of folate-polyethylene glycol (PEG)-appended dendrimer (G3) conjugate with α-cyclodextrin as DNA carriers to tumor cells

Octreotide-Modified N-Octyl-O, N-Carboxymethyl Chitosan Micelles as Potential Carriers for Targeted Antitumor Drug Delivery

Contact Info

Product

Resources

About